The role of a CEO in an early biotech start-up
An early biotech start-up needs a CEO who can see what the company could become and turn that ambition into a business that people are willing to fund, join and buy from. Scientific understanding matters, but the role also demands commercial judgement, financial competence and the ability to communicate clearly with people who may have little technical knowledge.
The CEO is responsible for connecting the technology to a market, securing the resources to develop it, and giving the team a credible direction. That requires both a persuasive account of the future and a disciplined approach to the work needed to get there.
Understand the technology and explain its value
A CEO needs a sound overview of the technology: what it does, how well it has been demonstrated, what differentiates it and where its limitations lie. They must be able to question technical assumptions and understand how development, manufacturing and regulatory requirements affect the business.
They also need specialists whose expertise goes deeper than their own. The CEO’s responsibility is to bring that expertise together and make informed decisions.
The harder communication task is often explaining the opportunity to a non-technical audience. An investor or prospective customer needs to understand whose problem the company solves, why existing solutions are inadequate and why this particular technology offers a worthwhile improvement.
For an industrial biotech company, explaining an enzyme’s molecular properties may be useful later. The opening conversation should establish whether it can reduce processing costs, improve product quality or solve a production problem, and what evidence supports that claim.
Give the company a commercially credible vision
The CEO must look beyond the current experiment and describe a plausible business. Who will buy the product? How will it reach them? Will the company manufacture, license its technology or develop products with partners? Which initial application offers the strongest route to revenue?
A broad technology platform may support many applications, but a young company needs priorities. The CEO must decide which opportunity deserves scarce time and capital, and explain why other opportunities can wait.
Baum and Silverman's research on biotechnology start-ups examined technology, alliances, and human capital in venture financing and subsequent performance. Their findings highlight the importance of considering management and relationships alongside the technology itself. [1] A credible vision therefore includes the organisation and partnerships needed to deliver it.
Make the pitch clear in five minutes or twenty
Talking to investors is an art that requires preparation, listening and the ability to get to the point quickly. The audience should understand the company’s value proposition before hearing a detailed account of its science.
A five-minute pitch should establish the problem, the solution, the evidence, the commercial opportunity and the funding request. A twenty-minute presentation should develop the same argument with more detail on competition, intellectual property, development milestones, financial assumptions and the team.
These timings are practical presentation formats, rather than research-established rules. The essential skill is choosing the information that matters to the audience and the decision being sought.
Clark’s study of business angels found that presentation quality and content were associated with initial investor interest, with clarity and structure featuring in investors’ assessments. [2] Although the study was small and was not specific to biotech, it reinforces the value of making a complex opportunity understandable.
The CEO should be able to answer, plainly: What are we building? Why should anyone care? Why can we succeed? What will this investment allow us to prove?
Know the finances and negotiate with judgement
The CEO must understand the financial assumptions behind the business. This includes cash flow, monthly expenditure, the time remaining before cash runs out, development costs, pricing and the economics of delivering the product.
Revenue projections need a defensible basis. A forecast should connect to assumptions about customer adoption, production capacity, achievable prices and the time required to reach the market. The CEO should understand how delays, lower yields or slower sales would affect the funding requirement.
Company valuation requires similar judgement. Early biotech valuations depend heavily on uncertain future outcomes. A CEO must understand how development progress, intellectual property, market potential and financing terms influence the negotiation, while drawing on appropriate financial and legal advice.
The headline valuation is only one part of a deal. Ownership dilution, board rights, investor protections, licensing exclusivity and future obligations can shape the company for years. The CEO needs to understand those consequences before agreeing to terms.
Be ready when investor interest becomes serious
A good pitch should have a current business plan and financial model behind it. Once an investor expresses interest, the company should be able to provide supporting information promptly and consistently.
That means maintaining an organised set of documents covering financial assumptions, ownership, intellectual property, technical evidence, development plans, material contracts and the intended use of funds. Share confidential information through appropriate access arrangements.
Cardon, Mitteness and Sudek found that preparedness positively influenced angel investors’ evaluations across 1,995 assessments of 133 live pitches. [3] The practical lesson is that enthusiasm becomes more convincing when the CEO can substantiate the opportunity.
Every important claim in the pitch should connect to evidence or a clearly identified assumption. Differences between the presentation, business plan and financial model invite questions about how well the company understands its own business.
Keep operations lean and build essential capabilities
A young company cannot afford to build every function internally. The CEO must distinguish capabilities that create lasting competitive value from work that external specialists can perform effectively.
Depending on the business, outsourcing may include accounting, legal support, specialist testing, regulatory advice or manufacturing. Critical scientific knowledge, product direction and the ability to assess external work may need to remain within the organisation.
Outsourcing still requires ownership. Someone inside the company must define the work, assess quality, protect intellectual property and ensure that useful knowledge is retained.
Baum, Calabrese and Silverman found that the composition of Canadian biotech start-ups’ alliance networks was associated with differences in early performance, particularly innovation. [4] Partnerships deserve deliberate selection and active management.
Inspire the team through everyday leadership
The CEO’s vision must also make sense to the people doing the work. Employees need to understand how their contributions support the company’s priorities and what progress looks like.
Leading by example means preparing thoroughly, respecting expertise, keeping commitments and taking responsibility for difficult decisions. It also means being honest about uncertainty and making it safe for people to report disappointing results early.
A CEO who listens carefully can adapt the plan when evidence changes. A CEO who explains decisions clearly helps the team maintain confidence through that change.
The role ultimately brings ambition and execution together. The CEO must make the company’s potential understandable, secure the resources to pursue it and build a team capable of delivering the next meaningful milestone.
References
Research articles identified through Consensus.
[1] Baum, J., and Silverman, B. (2004). Picking winners or building them? Alliance, intellectual, and human capital as selection criteria in venture financing and performance of biotechnology startups. Journal of Business Venturing, 19, 411–436. DOI: 10.1016/S0883-9026(03)00038-7.
[2] Clark, C. (2008). The impact of entrepreneurs’ oral ‘pitch’ presentation skills on business angels’ initial screening investment decisions. Venture Capital, 10, 257–279. DOI: 10.1080/13691060802151945.
[3] Cardon, M., Mitteness, C., and Sudek, R. (2017). Motivational Cues and Angel Investing: Interactions among Enthusiasm, Preparedness, and Commitment. Entrepreneurship Theory and Practice, 41, 1057–1085. DOI: 10.1111/etap.12255.
[4] Baum, J., Calabrese, T., and Silverman, B. (2000). Don’t go it alone: Alliance network composition and startups’ performance in Canadian biotechnology. Strategic Management Journal, 21, 267–294. DOI: 10.1002/(SICI)1097-0266(200003)21:3<267::AID-SMJ89>3.0.CO;2-8.
Comments